摘要
Purpose: A phase II trial was conducted to evaluate the therapeutic efficacy and safety profiles of frontline concurrent chemoradiotherapy (CCRT) plus consolidation chemotherapy for patients with stage I/II nasal natural killer/T-cell lymphoma (NKTCL). Patients and methods: Patients with newly diagnosed, measurable stage I/II nasal NKTCL were eligible. The CCRT included two cycles of the DEP regimen (dexamethasone, etoposide, and cisplatin) every 4 wk with concurrent 5040 cGy radiation in 28 fractions for 5 wk. Patients without disease progression after CCRT were subjected to two cycles of DVIP consisted of dexamethasone, etoposide, ifosphamide, mesna, and cisplatin every 4 wk. The primary endpoint was tumor response rate, and secondary endpoints were survival and toxicities. This phase II study has been registered in the ClinicalTrials.gov (NCT00292695). Results: Thirty-three patients received CCRT, and 29 patients received two cycles of consolidation DVIP after CCRT. Among the 32 evaluable patients, 20 achieved complete response and 6 achieved partial response. The overall and complete response rate was 81% (95% CI, 68-95%) and 63% (95% CI, 46-79%), respectively. The 2-yr and 5-yr progression-free survival rate for intention-to-treat population was 64% (95% CI, 47-80%) and 60% (95% CI, 39-73%), respectively; while the corresponding overall survival rate was 73% (95% CI, 57-88%) and 66% (95% CI, 50-83%), respectively. The most common treatment-related grade 3/4 adverse event was leukopenia (85%). Conclusion: Frontline CCRT plus consolidation chemotherapy is feasible and effective for treating localized nasal NKTCL.
| 原文 | English |
|---|---|
| 頁（從 - 到） | 130-137 |
| 頁數 | 8 |
| 期刊 | European Journal of Haematology |
| 卷 | 94 |
| 發行號 | 2 |
| DOIs | |
| 出版狀態 | Published - 2015 二月 1 |
指紋
All Science Journal Classification (ASJC) codes
- Hematology
引用此文
}
Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. / Tsai, Hui Jen; Lin, Sheng Fung; Chen, Chu Chih; Chen, Tsai Yun; Su, Wu Chou; Hwang, Wen Li; Lin, Jin Ching; Chiou, Tzeon Jye; Kao, Weio Yau; Chiu, Chang Fang; Chang, Yi Fang; Chang, Jeffrey S.; Chang, Ming Chih; Su, Ih Jen.
於: European Journal of Haematology, 卷 94, 編號 2, 01.02.2015, p. 130-137.研究成果: Article
TY - JOUR
T1 - Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma
AU - Tsai, Hui Jen
AU - Lin, Sheng Fung
AU - Chen, Chu Chih
AU - Chen, Tsai Yun
AU - Su, Wu Chou
AU - Hwang, Wen Li
AU - Lin, Jin Ching
AU - Chiou, Tzeon Jye
AU - Kao, Weio Yau
AU - Chiu, Chang Fang
AU - Chang, Yi Fang
AU - Chang, Jeffrey S.
AU - Chang, Ming Chih
AU - Su, Ih Jen
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Purpose: A phase II trial was conducted to evaluate the therapeutic efficacy and safety profiles of frontline concurrent chemoradiotherapy (CCRT) plus consolidation chemotherapy for patients with stage I/II nasal natural killer/T-cell lymphoma (NKTCL). Patients and methods: Patients with newly diagnosed, measurable stage I/II nasal NKTCL were eligible. The CCRT included two cycles of the DEP regimen (dexamethasone, etoposide, and cisplatin) every 4 wk with concurrent 5040 cGy radiation in 28 fractions for 5 wk. Patients without disease progression after CCRT were subjected to two cycles of DVIP consisted of dexamethasone, etoposide, ifosphamide, mesna, and cisplatin every 4 wk. The primary endpoint was tumor response rate, and secondary endpoints were survival and toxicities. This phase II study has been registered in the ClinicalTrials.gov (NCT00292695). Results: Thirty-three patients received CCRT, and 29 patients received two cycles of consolidation DVIP after CCRT. Among the 32 evaluable patients, 20 achieved complete response and 6 achieved partial response. The overall and complete response rate was 81% (95% CI, 68-95%) and 63% (95% CI, 46-79%), respectively. The 2-yr and 5-yr progression-free survival rate for intention-to-treat population was 64% (95% CI, 47-80%) and 60% (95% CI, 39-73%), respectively; while the corresponding overall survival rate was 73% (95% CI, 57-88%) and 66% (95% CI, 50-83%), respectively. The most common treatment-related grade 3/4 adverse event was leukopenia (85%). Conclusion: Frontline CCRT plus consolidation chemotherapy is feasible and effective for treating localized nasal NKTCL.
AB - Purpose: A phase II trial was conducted to evaluate the therapeutic efficacy and safety profiles of frontline concurrent chemoradiotherapy (CCRT) plus consolidation chemotherapy for patients with stage I/II nasal natural killer/T-cell lymphoma (NKTCL). Patients and methods: Patients with newly diagnosed, measurable stage I/II nasal NKTCL were eligible. The CCRT included two cycles of the DEP regimen (dexamethasone, etoposide, and cisplatin) every 4 wk with concurrent 5040 cGy radiation in 28 fractions for 5 wk. Patients without disease progression after CCRT were subjected to two cycles of DVIP consisted of dexamethasone, etoposide, ifosphamide, mesna, and cisplatin every 4 wk. The primary endpoint was tumor response rate, and secondary endpoints were survival and toxicities. This phase II study has been registered in the ClinicalTrials.gov (NCT00292695). Results: Thirty-three patients received CCRT, and 29 patients received two cycles of consolidation DVIP after CCRT. Among the 32 evaluable patients, 20 achieved complete response and 6 achieved partial response. The overall and complete response rate was 81% (95% CI, 68-95%) and 63% (95% CI, 46-79%), respectively. The 2-yr and 5-yr progression-free survival rate for intention-to-treat population was 64% (95% CI, 47-80%) and 60% (95% CI, 39-73%), respectively; while the corresponding overall survival rate was 73% (95% CI, 57-88%) and 66% (95% CI, 50-83%), respectively. The most common treatment-related grade 3/4 adverse event was leukopenia (85%). Conclusion: Frontline CCRT plus consolidation chemotherapy is feasible and effective for treating localized nasal NKTCL.
UR - http://www.scopus.com/inward/record.url?scp=84922846170&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922846170&partnerID=8YFLogxK
U2 - 10.1111/ejh.12405
DO - 10.1111/ejh.12405
M3 - Article
C2 - 24957163
AN - SCOPUS:84922846170
VL - 94
SP - 130
EP - 137
JO - European Journal of Haematology
JF - European Journal of Haematology
SN - 0902-4441
IS - 2
ER -